ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer.
2/5 보강
TL;DR
The design and rationale for ToPCourT, an open label, single-arm, phase II trial to evaluate the efficacy of trilaciclib in combination with pembrolizumab, gemcitabine, and carboplatin in patients with locally advanced unresectable or metastatic TNBC, are described.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: locally advanced unresectable or metastatic TNBC who have received ≤3 lines of therapy in the metastatic setting
I · Intervention 중재 / 시술
≤3 lines of therapy in the metastatic setting
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Key secondary endpoints include progression-free survival, duration of response, and overall survival. www.clinicaltrials.gov identifier is NCT06027268.
OpenAlex 토픽 ·
Advanced Breast Cancer Therapies
HER2/EGFR in Cancer Research
Cancer-related Molecular Pathways
The design and rationale for ToPCourT, an open label, single-arm, phase II trial to evaluate the efficacy of trilaciclib in combination with pembrolizumab, gemcitabine, and carboplatin in patients wit
APA
Megan B. Sears-Smith, Ashley G. Matusz-Fisher, et al. (2026). ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer.. Future oncology (London, England), 22(8), 911-917. https://doi.org/10.1080/14796694.2026.2639737
MLA
Megan B. Sears-Smith, et al.. "ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer.." Future oncology (London, England), vol. 22, no. 8, 2026, pp. 911-917.
PMID
41810725 ↗
Abstract 한글 요약
Triple-negative breast cancer (TNBC) is a clinically aggressive and difficult to treat malignancy. It has a poorer prognosis when compared to the hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-positive subtypes. Due to the lack of targetable receptors, cytotoxic chemotherapy is often the backbone of therapy. Although effective, its use eventually becomes limited due to toxicity and resistance. Trilaciclib is an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor. Preclinical data showed that transient CDK4/6 inhibition with trilaciclib enhances and lengthens the duration of antitumor responses induced by a combination of chemotherapy and immune checkpoint inhibition. Herein, we describe the design and rationale for ToPCourT, an open label, single-arm, phase II trial. This study will evaluate the efficacy of trilaciclib in combination with pembrolizumab, gemcitabine, and carboplatin in patients with locally advanced unresectable or metastatic TNBC who have received ≤3 lines of therapy in the metastatic setting. The primary endpoint is overall response. Key secondary endpoints include progression-free survival, duration of response, and overall survival. www.clinicaltrials.gov identifier is NCT06027268.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Triple Negative Breast Neoplasms
- Female
- Antineoplastic Combined Chemotherapy Protocols
- Gemcitabine
- Antibodies
- Monoclonal
- Humanized
- Deoxycytidine
- Carboplatin
- Clinical Trials
- Phase II as Topic
- Pyrroles
- Treatment Outcome
- Pyrimidines
- Spiro Compounds
- CDK4/6 inhibitor
- clinical trial
- gemcitabine
- pembrolizumab
- phase II
- triple-negative breast cancer
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.